Notice for sotatercept (Merck Sharp & Dohme (Australia) Pty Ltd)
Active ingredients
sotatercept
Date of review outcome
Lapse date
Type
Orphan drug
Dosage form(s)
lyophilized powder for solution for injection
Indication
For the treatment of patients with Pulmonary Arterial Hypertension (PAH),
Therapeutic area
Cardiovascular